Bibliography

Bennett DA, Schneider JA, Arvanitakis Z, et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology. 2006;66(12):1837–1844.

Bennett DA, Schneider JA, Wilson RS, Bienias JL, Arnold SE. Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Archives of Neurology. 2004;61(3):378–384.

Buckley RF, Townsend DL, Birkenbihl CJ, et al. Prognostic Value of Blood-Based P-Tau217 Levels for Progression to Cognitive Impairment. *JAMA.* 2026;336(11):950–959. doi:10.1001/jama.2026.12556

Cao Q, Tan C-C, Xu W, et al. The Prevalence of Dementia: A Systematic Review and Meta-Analysis. *Journal of Alzheimer's Disease*. 2020;73(3):1157-1166.

Chan JYC, Yau STY, Kwok TCY, Tsoi KKF. Diagnostic performance of digital cognitive tests for the identification of MCI and dementia: A systematic review. Ageing Res Rev. 2021 Dec;72:101506.

Chatanaka MK, Pascual Lorén M, Diamandis EP. Is screening for Alzheimer's disease ready for prime time? Ask Wilson and Jungner. Crit Rev Clin Lab Sci. 2025 Dec;62(8):631-645.

Ding Z, Lee TL, Chan AS. Digital Cognitive Biomarker for Mild Cognitive Impairments and Dementia: A Systematic Review. J Clin Med. 2022 Jul 19;11(14):4191.

Dou X, Lenzen S, Connelly LB, Lin R. Generational Differences in Age-Specific Dementia Prevalence Rates. *JAMA Netw Open.* 2025;8(6):e2513384.

Dubois B, Villain N, Schneider L, et al. Alzheimer Disease as a Clinical-Biological Construct—An International Working Group Recommendation. *JAMA Neurol.* 2024;81(12):1304–1311.

Fowler NR, Perkins A, Gao A, Sachs G, Boustani MA. Risks and benefits of screening for dementia in primary care: the IU CHOICE Trial. J Am Ger Soc. 2020;68:535-543.

Fowler NR, Perkins AJ, Gao S, Bakas T, Head KJ, Higbie A, Baucco C, Callahan CM, Williams-Farrelly MM, Boustani MA. Benefits and Harms of Dementia Screening for Family Members of Older Adults: A Randomized Clinical Trial. JAMA Intern Med. 2026 Jun 1;186(6):689-700.

Grande, G., Valletta, M., Rizzuto, D. *et al.* Blood-based biomarkers of Alzheimer's disease and incident dementia in the community. *Nat Med* 31, 2027–2035 (2025).

Jack CR, Andrews JS, Beach TG, et al. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. Alzheimer's Dement. 2024; 20: 5143–5169.

Jack C Hu M, Wiste H et al. Lifetime and 10-year absolute risk of cognitive impairment in relation to amyloid PET severity: a retrospective, longitudinal cohort study. The Lancet Neurology, 24, 1016-1025

Manly JJ, Jones RN, Langa KM, et al. Estimating the Prevalence of Dementia and Mild Cognitive Impairment in the US: The 2016 Health and Retirement Study Harmonized Cognitive Assessment Protocol Project. *JAMA Neurol.* 2022;79(12):1242–1249.

Nelson PT, Alafuzoff I, Bigio EH, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. Journal of Neuropathology & Experimental Neurology. 2012;71(5):362–381.

Ossenkoppele, R., Pichet Binette, A., Groot, C. *et al.* Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. *Nat Med* 28, 2381–2387 (2022).

Palmqvist S, Whitson HE, Allen LA, Suarez-Calvet M, Galasko D, Karikari TK, Okrahvi HR, Paczynski M, Schindler SE, Teunissen CE, Zetterberg H, Carrillo MC, Edelmayer RM, Mahinrad S, McAteer MB, Kahale LA, Pahlke S, Tampi MP. Alzheimer's Association Clinical Practice Guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer's disease within specialized care settings. Alzheimers Dement. 2025 Jul;21(7):e70535. doi: 10.1002/alz.70535.

Rostamzadeh A, Bohr L, Wagner M, Baethge C, Jessen F. Progression of Subjective Cognitive Decline to MCI or Dementia in Relation to Biomarkers for Alzheimer Disease: A Meta-analysis. Neurology. 2022 Oct 25;99(17):e1866-e1874.

Schindler SE, Wolk DA. Predicting Risk of Cognitive Impairment With Alzheimer Disease Blood Biomarkers. *JAMA.* 2026;336(11):923–925. doi:10.1001/jama.2026.13322

Schnieder J. Neuropathology of Dementia Disorders. Continuum. 2022. 28(3):834-851

US Preventive Services Task Force. Screening for Cognitive Impairment in Older Adults: US Preventive Services Task Force Recommendation Statement. *JAMA.* 2020;323(8):757–763.